Information Provided By:
Fly News Breaks for January 10, 2020
Jan 10, 2020 | 12:50 EDT
Goldman Sachs analyst Paul Choi kept a Sell rating and $17 price target on Nektar Therapeutics (NKTR) following the company's amended collaboration agreement with Bristol-Myers Squibb (BMY), which he said provides visibility on the path forward for bempegaldesleukin + Opdivo. While the analyst expects Nektar to trade up following the news, he added that "in the absence of data we do not expect significant credit to be attributed to these additional indications in the near term."
News For NKTR;BMY From the Last 2 Days
There are no results for your query NKTR;BMY